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By letter of 6 April 1990 the Council consulted the European Parliament, 
pursuant to Article 100a of the EEC Treaty, on the Commission proposal for a 
Council directive widening the scope of Directives 65/65/EEC and 75/319/EEC on 
the approximation of the laws of the Member States on medicinal products and 
laying down additional provisions on homeopathic medicinal products and for a 
Council directive widening the scope of Directive 81/851/EEC on the 
approximation of the laws of the Member States on veterinary medicinal 
products and laying down additional provisions on homeopathic veterinary 
medicinal products. 
At the sitting of 14 May 1990 the President of Parliament announced that he 
had referred these proposals to the Committee on the Environment, Public 
Health and Consumer Protection as the committee responsible and to the 
Committee on Economic and Monetary Affairs and Industrial Policy, the 
Committee on Agriculture, Fisheries and Rural Development and the Committee on 
Legal Affairs and Citizens' Rights for their opinions. 
At its meeting of 30 May 1990 the Committee on the Environment, Public Health 
and Consumer Protection appointed Mr Chanterie rapporteur. 
It considered the Commission's proposals and the draft report at its meetings 
of 26 September and 18 December 1990 and 21 March 1991. 
At the last such meeting it approved the draft legislative resolutions by 22 
votes in favour with 2 abstentions. 
The following took part in the vote: Collins, chairman; Schleicher and 
Scott-Hopkins, vice-chairmen; Chanterie, rapporteur; Balfe (for Green, 
pursuant to Rule 111 (2) of the Rules of Procedure); Bowe, Diez de Rivera, 
Icaza, Fernex (for Monnier-Besombes, pursuant to Rule 111(2) of the Rules of 
Procedure), Florenz, Guidolin, Caroline Jackson, Jensen, Kuhn, Lannoye (for 
Amendola), Nordmann (for Veil), Oomen-Ruijten, Partsch, Pimenta, Pollack, 
Quistorp, Roth-Behrendt, Llewellyn Smith, Valverde Lopez and Vernier. 
The opinions of the Committee on Economic and Monetary Affairs and Industrial 
Policy and of the Committee on Agriculture, Fisheries and Rural Development 
are attached. The Committee on Legal Affairs and Citizens' Rights decided on 
28 June 1990 not to deliver an opinion. 
The report was tabled on 11 April 1991. 
The deadline for tabling amendments will appear in the draft agenda for the 
part-session at which the report is to be considered. 
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A. 
I. Proposal from the Commission to the Council for a Directive widening the 
scope of Directives 65/65/EEC and 75/319/EEC on the approximation of the 
laws of the Member States on medicinal products and laying down 
additional provisions on homeopathic medicinal products 
Commission text1 Alllendaents 
(Amendment No. 1) 
First recital 
Whereas differences currently 
existing between the provisions laid 
down by law 1 regulation or 
administrative action in the Member 
States may hinder trade in 
homeopathic medicinal products 
within the Community; 
Whereas differences currently 
existing between the provisions laid 
down by law 1 regulation or 
administrative action in the Member 
States may hinder trade in 
homeopathic medicinal products 
within the Community and thus lead 
to discrimination and distortion of 
competition between manufacturers of 
these products; 
(Amendment No. 2) 
Recital 2a - ~ 
whereas freedom of 
regard to therapy 
safeguarded 
(Amendment No. 3) 
Recital 3a - ~ 
choice with 
needs to be 
whereas allopathy, anthroposophy and 
homeopathy should be regarded as 
different approaches which each have 
their own merits and which may in 
many cases complement each other; 
For complete text see COM(90) 0072 final- OJ No. C 108 1 01.05.1990 1 p. 010. 
DOC_EN\RR\107695 
- 4 - PE 144.139/fin. 
(Amendment No. 4) 
Recital 4a - new 
Whereas, although these differences 
in status currently prevent total 
harmonization of alternative 
medicines practised within the EEC 
(particularly with regard to 
pharmacopoeias, medical practice, 
reimbursement from social security 
funds and teaching), this exercise 
should be undertaken within a 
reasonable period; whereas, 
therefore, it is appropriate to 
recognize certain national 
homeopathic and anthroposophical 
traditions without imposing them 
throughout the Community; 
(Amendment No. 5) 
Recital 4b - new 
Whereas anthroposophical medicine 
plays a significant role in 
alternative medicine in some Member 
States and whereas the interests of 
patients choosing this type of 
medicine need to be safeguarded; 
(Amendment No. 6) 
Eighth recital 
Whereas, having regard to the 
particular characteristics of these 
medicinal products, such as their 
very low content of active 
principles and the difficulty of 
applying to them the conventional 
statistical methods relating to 
clinical trials, it is appropriate 
to provide a simplified registration 
system for those traditional 
homeopathic medicinal products which 
are placed on the market without 
specific therapeutic indications in 
a preparation which does not present 
a risk for the patient; 
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Whereas, having regard to the 
particular characteristics of these 
medicinal products, such as their 
very low content of active 
principles and the difficulty of 
applying to them the conventional 
statistical methods relating to 
clinical trials, it is appropriate 
to provide a simplified registration 
system for those traditional 
homeopathic medicinal products 
which are placed on the market 
without specific therapeutic 
indications in a preparation and 
dosage which does not present a risk 
for the patient; 
PE 144.139/fin. 
(Amendment No. 7) 
Ninth recital 
Whereas 1 however 1 the usual rules 
governing the authorization to 
market medicinal products should be 
applied to a homeopathic medicinal 
product marketed with therapeutic 
indications or in a form which may 
present risks which must be balanced 
against the desired therapeutic 
effect; 
whereas those Member States which 
have a homeopathic tradition should 
be able to apply particular rules 
for the evaluation of tests and 
trials intended to establish the 
safety and efficacy of these 
medicinal products provided that 
they notify them to the Commission; 
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Whereas 1 however 1 the usual rules 
governing the authorization to 
market medicinal products should be 
applied to a homeopathic medicinal 
product marketed with therapeutic 
indications or in a form which may 
present risks which must be balanced 
against the desired therapeutic 
effect; whereas the necessary 
provisions for authorization to 
market homeopathic medicinal 
products with therapeutic 
indications should take account of 
the characteristics of the 
homeopathic treatment; 
whereas those Member States which 
have a homeopathic tradition should 
be able to apply particular rules 
for the evaluation of tests and 
trials intended to establish the 
safety and efficacy of these 
medicinal products provided that 
they notify them to the Commission; 
PE 144.139/fin. 
(Amendment No. 8) 
Article 1 
For the purposes of this Directive 
'homeopathic medicinal product' 
shall mean any medicinal product 
prepared in accordance with a 
homeopathic manufacturing procedure 
described by the European 
Pharmacopoeia, or in the absence 
thereof, by the official 
pharmacopoeia of a Member State. 
Homeopathic preparations are 
produced from products, substances 
or compositions called homeopathic 
stocks by successive dilutions or bv 
grinding. 
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For the purposes of this Directive 
'homeopathic medicinal product' 
shall mean any pharmaceutical 
preparation prepared in accordance 
with a homeopathic manufacturing 
procedure described by the European 
Pharmacopoeia, or in the absence 
thereof, by the official 
pharmacopoeia of a Member State. 
A homeopathic medicinal product may 
also contain of a number of 
different components. 
For the purposes of this Directive 
anthroposophical medicinal products 
described by an official 
pharmacopoeia shall be treated as 
egui valent to homeopathic medicinal 
products. 
Homeopathic preparations are 
produced from products, substances 
or compositions called homeopathic 
stocks by successive dilutions and 
potentiation. 
A homeopathic preparation may 
contain, with the exception of 
catalysts, only homeopathic stocks 
in a minimum dilution of 1:10. 
PE 144.139/fin. 
(Amendment No. 9) 
Article 7(1) 
1. Homeopathic medicinal products 
shall be subject to a simplified 
registration procedure if they 
satisfy all of the following 
conditions: 
they are administered orally or 
externally; 
- they are marketed without any 
specific therapeutic indication, 
whether on the labelling of the 
product or in any accompanying 
product information; 
- there is a sufficient degree of 
dilution to guarantee the safety 
of the preparation; in 
particular, the preparation shall 
contain less than one part per 
million of any active principle 
which is subject to the 
requirement of a medical 
prescription. 
1 . Homeopathic medicinal products 
shall be subject to a simplified 
registration procedure if they 
satisfy all of the following 
conditions: 
- they are administered in 
accordance with the methods 
described in the European 
Pharmacopoeia, or in the absence 
thereof, in the official 
homeopathic pharmacopoeia of a 
Member State; 
- they are marketed without any 
specific therapeutic indication, 
whether on the labelling of the 
product or in any accompanying 
product information; 
- there is a sufficient degree of 
dilution to guarantee the safety 
of the preparation per dosage; in 
particular, the preparation shall 
contain no more than the quantity 
permitted per dosage for that 
method of administration of any 
active principle which is subject 
to the requirement of a medical 
prescription. 
These maximum permitted quantities 
shall be specified for each active 
principle in an annex to this 
Directive. 
- in particular, 
shall contain no 
the preparation 
more than one 
part per thousand of any active 
principle which is subject to the 
requirement of a medical 
prescription. 
(Amendment No. 10) 
Article 7(2) 
In addition to the clear mention of 
the words 'homeopathic medicinal 
product', the labelling and 
packaging of the medicinal products 
referred to in paragraph 1 shall 
consist of the following information 
and no other information: 
- the scientific name of the stock 
followed by the degree of 
dilution, using the symbols used 
in the official pharmacopoeia of 
the Community, 
DOC_EN\RR\107695 - 8 -
In addition to the clear mention of 
the words 'homeopathic medicinal 
product', the labelling and 
packaging of the medicinal products 
referred to in paragraph 1 shall 
consist of the following information 
and no other informati0n: 
- name and address of the person 
responsible for marketing, and of 
the manufacturer, 
- method of administration, 
PJ: 144.139/fin. 
- expiry date, in plain language, 
- special storage precautions, if 
any, 
-manufacturer's batch number, 
- registration number. 
the scientific name of the of the 
homeopathic stock or stocks 
followed by the strength or 
strengths, using the symbols used 
in the official pharmacopoeia of 
the Community, 
- name and address of the person 
responsible for marketing, and of 
the manufacturer, 
- method of administration, 
- expiry date, in plain language, 
- special storage precautions, if 
any, 
-manufacturer's batch number, 
- registration number. 
(Amendment No. 11) 
Article 7(2) 
Seventh indent (new) 
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- a sentence advising the user to 
consult a competent homeopathic 
therapist whilst using the 
medicinal product if the symptoms 
persist. 
PE 14•L 139/fin. 
(Amendment No. 12) 
Article 8 
An application for a simplified 
registration submitted by the person 
responsible for marketing may cover 
a series of preparations derived 
from the same homeopathic stock. 
The following documents shall be 
included with the application in 
order to demonstrate, in particular, 
the pharmaceutical quality and the 
batch consistency of the products 
concerned: 
-scientific name of the 
homeopathic stock, together with 
a mention of the various routes 
of administration, pharmaceutical 
forms and dilutions to be 
registered; 
- dossier describing how the 
homeopathic stock is obtained and 
controlled, and justifying its 
homeopathic nature, on the basis 
of an adequate homeopathic 
bibliography; 
- manufacturing and control file 
for each pharmaceutical form and 
a description of the method of 
dilution; 
- manufacturing authorization for 
the preparations concerned; 
- copies of any registrations or 
authorizations obtained for the 
same preparations in other Member 
States; 
- one or more specimens or mock-
ups of the sales presentation of 
the preparations to be registered. 
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An application for a simplified 
registration submitted by the person 
responsible for marketing may cover 
a series of preparations derived 
from the same homeopathic stock or 
stocks. The following documents 
shall be included with the 
application in order to demonstrate, 
in particular, the pharmaceutical 
quality and the batch consistency of 
the products concerned: 
-scientific name of the 
homeopathic stock or stocks, 
together with a mention of the 
various routes of administration, 
pharmaceutical forms and strengths 
to be registered; 
- dossier describing how the 
homeopathic stock or stocks 
is/are obtained and controlled, 
and justifying its homeopathic 
nature, on the basis of an 
adequate homeopathic bibliography; 
- manufacturing and control file 
for each pharmaceutical form and 
a description of the method of 
dilution and potentiation; 
- manufacturing authorization for 
the preparations concerned; 
- copies of any registrations or 
authorizations obtained for the 
same preparations in other Member 
States; 
- one or more specimens or mock-
ups of the sales presentation of 
the preparations to be registered. 
PE 144.139/fin. 
(Amendment No. 13) 
Article 9(1) 
Homeopathic medicinal products other 
than those referred to in Article 7 
shall be authorized and labelled in 
accordance with the provisions of 
Articles 5 to 21 of Directive 
65/65/EEC and Articles 1 to 7 of 
Directive 75/319/EEC, including the 
prov1s1ons concerning proof of 
therapeutic effect. 
Homeopathic and anthroposophical 
medicinal products other than those 
referred to in Article 7 shall be 
authorized and labelled in 
accordance with the provisions of 
Articles 5 to 21 of Directive 
65/65/EEC and Articles 1 to 7 of 
Directive 75/319/EEC, including the 
provisions concerning proof of 
therapeutic effect, whilst taking 
due account of the basic principles 
and special nature of homeopathic or 
anthroposophical medicine. 
(Amendment No. 14) 
Article 10(2)a (~) 
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The Commission is instructed, within 
5 vears of the entry into force of 
this Directive, to take all measures 
necessary to ensure that the status 
of alternative medicine is 
harmonized, particularly in the 
following respects: 
-adoption of a European 
Pharmacopoeia, 
adoption of a Directive on the 
legitimate practice of 
alternative medicines, 
arrangements for social security 
organizations to refund the cost 
of services and medicinal 
products, 
- organization of officially 
recognized teaching; 
(Amendment No. 15) 
Article 10(2b) (new) 
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3. Not later than 31 December 1995 
the Commission shall present a 
report to the Council and to the 
European Parliament concerning the 
operation of this Directive. 
PE 144.139/fin. 
A. 
DRAFT LEGISLATIVE RESOLUTION 
(Cooperation procedure: first reading) 
embodying the opinion of the European Parliament on the Commission proposal 
for a Council directive widening the scope of Directives 65/65/EEC and 
75/319/EEC on the approximation of the laws of the Member States on veterinary 
medicinal products and laying down additional provisions on homeopathic 
veterinary medicinal products 
The European Parliament, 
- having regard to the Commission proposal to the Council (COM(90) 0072 final 
- SYN 251) 1 , 
- having been consulted by the Council pursuant to Article 1 OOa of the EEC 
Treaty (C3-0112/90), 
- having regard to the report of the Committee on the Environment, Public 
Health and Consumer Protection and the op1n1ons of the Committee on 
Economic and Monetary Affairs and Industrial Policy and the Committee on 
Agriculture, Fisheries and Rural Development (A3-0093/91), 
1. Approves the Commission proposal subject to Parliament's amendments and 
in accordance with the vote thereon; 
2. Calls on the Commission to amend its proposal accordingly, pursuant to 
Article 149(3) of the EEC Treaty; 
3. Asks to be consulted again should the Council intend to make substantial 
modifications to the Commission proposal; 
4. Calls on the Council to incorporate Parliament's amendments in the common 
position that it adopts in accordance with Article 149(2)(a) of the EEC 
Treaty; 
6. Instructs its President to forward this opinion to the Council and 
Commission. 
1 OJ No. C 108, 1.5.1990, p. 10 
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II. Proposal from the Commission to the Council for a Directive widening the 
scope of Directive 85/851 /EEC on the approximation of the laws of the 
Member States on veterinary medicinal products and laying down additional 
provisions on homeopathic veterinary medicinal products 
Qommission text! Amendments 
(Amendment No. 16) 
First recital 
Whereas differences currently 
existing between the provisions laid 
down by law, regulation or 
administrative action in the Member 
States may hinder trade in 
homeopathic medicinal products within 
the Community; 
Whereas differences currently 
existing between the provisions laid 
down by law, regulation or 
administrative action in the Member 
States may hinder trade in 
homeopathic medicinal products 
within the Community and thus lead 
to discrimination and distortion of 
competition between manufacturers of 
these products; 
(Amendment No. 17) 
Recital 2a (~) 
whereas freedom of 
regard to therapy 
safeguarded 
(Amendment No. 18) 
Recital 4a (~) 
choice with 
needs to be 
Whereas, although these differences 
in status currently prevent total 
harmonization of alternative 
medicines practised within the EEC 
(particularly with regard to 
pharmacopoeias, medical practice, 
reimbursement from social security 
funds and teaching), this exercise 
should be undertaken within a 
reasonable period; 
1 For full text see COM(90) 0072 final- OJ C 108, 01.05.1990, p. 013 
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(Amendment No. 19) 
Eighth recital 
Whereas, having regard to the 
particular characteristics of these 
medicinal products, such as their 
very low content of active principles 
and the difficulty of applying to 
them the conventional statistical 
methods relating to clinical trials, 
it is appropriate to provide a 
simplified registration system for 
those traditional homeopathic 
veterinary medicinal products which 
are placed on the market without 
specific therapeutic indications in a 
preparation which does not present a 
risk for the animal or the consumer 
of animal products; 
Whereas, having regard to the 
particular characteristics of these 
medicinal products, such as their 
very low content of active 
principles and the difficulty of 
applying to them the conventional 
statistical methods relating to 
clinical trials, it is appropriate 
to provide a simplified registration 
system for those traditional 
homeopathic veterinary medicinal 
products which are placed on the 
market without specific therapeutic 
indications in a preparation and 
dosage which does not present a risk 
for the animal or the consumer of 
animal products; 
(Amendment No. 20) 
Article 
~·or the purposes of this Directive 
'homeopathic veterinary medicinal 
product' shall mean any veterinary 
medicinal product prepared in 
accordance with a homeopathic 
manufacturing procedure described by 
the European Pharmacopoeia, or in the 
absence thereof, by the official 
pharmacopoeia of a Member State. 
Homeopathic preparations are produced 
from products, substances or 
compositions called homeopathic 
stocks by successive dilutions or by 
grinding. 
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For the purposes of this Directive 
'homeopathic veterinary medicinal 
product' shall mean any 
pharmaceutical preparation prepared 
in accordance with a homeopathic 
manufacturing procedure described by 
the European Pharmacopoeia, or in 
the absence thereof, by the official 
pharmacopoeia of a Member State. 
A homeopathic medicinal product may 
also contain of a number of 
different components. 
Homeopathic preparations are 
produced from products, substances 
or compositions called homeopathic 
stocks by successive dilutions and 
potentiation. 
Homeopathic preparations mav. 
contain with the exception of 
catalysts, only homeopathic stocks, 
in a minimum dilution of 1:10. 
PE 144.139/fin. 
(Amendment No. 21) 
Article 7(1) 
Homeopathic veterinary medicinal 
products shall be subject to a 
simplified registration procedure if 
they satisfy all of the following 
conditions: 
they are administered orally or 
externally; 
they are marketed without any 
specific therapeutic indication, 
whether on the labelling of the 
medicinal product or in any 
accompanying product information; 
there is a sufficient degree of 
dilution to guarantee the safety 
of the preparation, and in the 
case of homeopathic veterinary 
medicinal products intended for 
administration to food producing 
animals, to guarantee the absence 
of harmful residues in foodstuffs 
produced from these animals; in 
particular, the preparation shall 
contain less then one part per 
million of any active principle 
which is subject to the 
requirement of a veterinary 
prescription. 
Homeopathic veterinary medicinal 
products shall be subject to a 
simplified registration procedure if 
they satisfy all of the following 
conditions: 
- they are administered orally or 
externally or parenterally; 
- they are marketed without any 
specific therapeutic indication, 
whether on the labelling of the 
medicinal product or in any 
accompanying product information; 
- there is a sufficient degree of 
dilution to guarantee the safety 
of the preparation per dosage, and 
in the case of homeopathic 
veterinary medicinal products 
intended for administration to 
food producing animals, to 
guarantee the absence of harmful 
residues in foodstuffs produced 
from these animals; in particular, 
the preparation shall contain not 
more than the quantity permitted 
oer dosage for that method of 
administration of any active 
principle which is subject to the 
requirement of a veterinary 
prescription. 
- in particular, the preparation 
shall contain no more than one 
part oer thousand of any active 
principle which is subject to the 
requirement of a medical 
prescription. These maximum 
permitted quantities shall be 
specified. for each active 
principle, in an annex to this 
Directive. 
(Amendment No. 22) 
Article 7(2), second indent 
the scientific name of the stock 
followed by the degree of 
dilution, using the symbols used 
in the official pharmacopoeia of 
the Community, 
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- the scientific name of the stock 
or stocks followed by the strength 
or strengths, using the symbols 
used in the official pharmacopoeia 
of the Community, 
PE 144. 139/fin. 
(Amendment No. 23) 
Article 8 
An application for a simplified 
registration submitted by the person 
responsible for marketing may cover a 
series of preparations derived from 
the same homeopathic stock. The 
following documents shall be included 
with the application in order to 
demonstrate, in particular, the 
pharmaceutical quality and the batch 
to batch consistency of the products 
concerned: 
scientific name of the 
homeopathic stock, together with 
a mention of the various routes 
of administration, pharmaceutical 
forms and dilutions to be 
registered; 
dossier describing how the stock 
is obtained and controlled, and 
justifying its homeopathic 
nature, on the basis of an 
adequate homeopathic 
bibliography; 
manufacturing and control file 
for each pharmaceutical form and 
a description of the method of 
dilution; 
manufacturing authorization for 
the preparations concerned; 
copies of any registrations or 
authorizations obtained for the 
same preparations in other Member 
States; 
one or more specimens or mock-ups 
of the sales presentation of the 
preparations to be registered. 
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An application for a simplified 
registration submitted by the person 
responsible for marketing may cover 
a series of preparations derived 
from the same homeopathic stock or 
stocks. The following documents 
shall be included with the 
application in order to demonstrate, 
in particular, the pharmaceutical 
quality and the batch to batch 
consistency of the products 
concerned: 
scientific name of the 
homeopathic stock or stocks, 
together with a mention of the 
various routes of 
administration, pharmaceutical 
forms and strengths to be 
registered; 
dossier describing how the 
stock/stocks is/are obtained and 
controlled, and justifying 
its/their homeopathic nature, on 
the basis of an adequate 
homeopathic bibliography; 
manufacturing and control file 
for each pharmaceutical form and 
a description of the method of 
dilution and potentiation; 
manufacturing authorization for 
the preparations concerned; 
copies of any registrations or 
authorizations obtained for the 
same preparations in other 
Member States; 
one or more specimens or mock-
ups of the sales presentation of 
the preparations to be 
registered. 
documents guaranteeing the safety 
of the preparation and, in the 
case of veterinary medicinal 
products intended for 
administration to food producing 
animals, guaranteeing the absence 
of harmful residues; 
PE 144.139/fin. 
(Amendment No. 24) 
Article 9(1) 
Homeopathic veterinary medicinal 
products other than those referred 
to in Article 7 shall be authorized 
and labelled in accordance with the 
provisions of Articles 5 to 15 of 
Directive 81/851 /EEC, including the 
provisions concerning proof of 
therapeutic effect, and shall be 
labelled in accordance with the 
provisions of Articles 43 to 50 of 
Directive 81/851/EEC. 
Homeopathic veterinary medicinal 
products other than those referred 
to in Article 7 shall be authorized 
and labelled in accordance with the 
provisions of Articles 5 to 15 of 
Directive 81/851/EEC, including the 
provisions concerning proof of 
therapeutic effect, and shall be 
labelled in accordance with the 
provisions of Articles 43 to 50 of 
Directive 81/851/EEC, whilst taking 
due account of the basic principles 
and special nature of homeopathic or 
anthroposophical medicine; 
(Amendment No. 25) 
Article 9(1) 
Homeopathic veterinary medicinal 
products other than those referred 
to in Article 7 shall be authorized 
and labelled in accordance with the 
provisions of Articles 5 to 1 5 of 
Directive 81/851 /EEC, including the 
provisions concerning proof of 
therapeutic e'ffect, and shall be 
labelled in accordance with the 
provisions of Articles 43 to 50 of 
Directive 81/851/EEC. 
Homeopathic veterinary medicinal 
products other than those referred 
to in Article 7 shall be authorized 
and labelled in accordance with the 
provisions of Articles 5 to 15 of 
Directive 81/851/EEC, including the 
provisions concerning proof of 
therapeutic effect, and shall be 
labelled in accordance with the 
provisions of Articles 43 to 50 of 
Directive 81/851 /EEC. The product 
shall be clearly labeled 
1 homeopathic veterinary medicinal 
product 1 • 
(Amendment No. 26) 
Article 10(2)a - (new) 
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Not later than 31 December 1995 the 
Commission shall present a report to 
the Council and to the European 
Parliament concerning the operation 
of this Directive. 
PE 144.139/fin. 
A 
DRAF!' LEGISLA'HVE RESOLU"l'IOR 
(Cooperation procedure: first reading) 
embodying the op1n1on of the European Parliament on the Commission proposal 
for a Council directive widening the scope of Directive 81/851/EEC on the 
approximation of the laws of the Member States on veterinary medicinal 
products and laying down additional provisions on homeopathic veterinary 
medicinal products 
The European Parliament, 
having regard to the Commission proposal to the Council (COM(90) 0072 final 
- SYN 252) 1 I 
having been consulted by the Council pursuant to Article 100a of the EEC 
Treaty (C3-0113/90), 
having regard to the report of the Committee on the Environment, Public 
Health and Consumer Protection and the opinions of the Committee on 
Economic and Monetary Affairs and Industrial Policy and the Committee on 
Agriculture, Fisheries and Rural Development (A3-0093/91), 
1. Approves the Commission proposal subject to Parliament's amendments and in 
accordance with the vote thereon; 
2. Calls on the Commission to amend its proposal accordingly, pursuant to 
Article 149(3) of the EEC Treaty; 
3. Asks to be consulted again should the Council intend to make substantial 
modifications to the Commission proposal; 
4. Calls on the Council to incorporate Parliament's amendments in the common 
position that it adopts in accordance with Article 149(2) (a) of the EEC 
Treaty; 
6. Instructs its President to forward this opinion to the Council and 
Commission. 
OJ No. C 108, 1.5.1990, p. 13 
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B 
EXPLANATORY STATEMENT 
1. Introduction 
After rema1n1ng constant a long time, interest in alternative medicines, and 
not only homeopathy, has increased markedly in recent years. At Community 
level no success has yet been achieved in drawing up common arrangements for 
(trade in) alternative medicinal products. Directives 87/22/EEC1 and 
75/919/EEC2 established Community legislation covering medicinal products, but 
a few categories (immunological medicinal products, radiopharmaceuticals, 
medicinal products derived from human blood and homeopathic and other 
alternative medicinal products) were excluded. 
Three of these four gaps have now been filled by various directives. 3 After 
several attempts that failed due to the very divergent national standpoints on 
this sensitive subject, the Commission now proposed to regulate the trade in 
homeopathic medicinal products. 
2. Alternative medicines in Europe 
A study for the European Commission by Mr G. Sermeus of the Belgian Consumers' 
Association investigated the issue of alternative medicines, covering seven 
Community Member States (Belgium, Denmark, France, Federal Republic of 
Germany, Italy, the Netherlands and the United Kingdom) and also Finland and 
Switzerland. 
The most significant of its findings were: 
1 
2 
3 
Between 18 and 75% of the population, depending on the country, have 
consulted practitioners of alternative medicine at least once; 
Between 6 and 24% of the population of the countries 
consulted an alternative medical practitioner during 
months. 
in question had 
the previous 12 
One in four Belgians consulted a practitioner of alternative medicine at 
least once a year. In France and Finland, one in six people did so, in 
Denmark, the UK and West Germany, one in 11, in the Netherlands and 
Switzerland, one in 15; 
Homeopathy has proved to be by far the most significant alternative 
medicine, followed by acupuncture and manipulations (such as chiropractice 
and osteopathy), and then by herbal remedies, massage and paranormal 
OJ No. L 15, 17.1.1987, p. 38 
OJ No. L 147, 9.6.1978, p. 13 
Directive 89/342/EEC, OJ No. L 142, 25.5.1989, p. 14, on immunological 
medicinal products; Directive 89/343/EEC, OJ No. L 142, 25.5.1989, p. 16, 
on radiopharmaceuticals; Directive 89/381/EEC, OJ No. L 181, 28.6.1989, 
p. 45, on medicinal products derived from human blood. 
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methods. There is also anthroposophical medicine, and lastly a number of 
less frequent method such as iridology, water baths, thalassotherapy, diet 
therapy, healing, reflexology, etc.; 
Greater use has been made of alternative medicines by adults between the 
ages of 35 and 60 with a high level of education than by other sections of 
the population. In general terms, women have made more frequent use of 
them than men; 
3. The Commission proposal 
The Commission proposal concerns homeopathic medicinal products excluding 
medicinal products which are prepared according to magistral or officina! 
formulae. 
First of all, a series of provisions contained in Directive 75/319/EEC1 are 
applied to these medicinal products, giving EC consumers solid guarantees 
regarding the quality and harmlessness of homeopathic medicines. Thus, for 
example, the same requirements will apply to the manufacture, control, import 
and export of homeopathic medicinal products as to allopathic medicinal 
products with effect from 1 January 1993. 
The proposal represents the second - and extremely cautious - attempt to 
liberalize trade in homeopathic medicinal products. The Commission envisages 
harmonization of the conditions governing authorization for placing on the 
market. The proposal is still limited to products which come on the market 
only after 1 January 1993. A significant distinction is drawn between 
homeopathic medicinal products classified as totally harmless and all other 
homeopathic medicinal products. In order to belong to the first category, the 
medicinal product must be administered orally or externally, may not be 
claimed to have any therapeutic effects and must be diluted to less than one 
part per million of active principle ( = D6). A simplified registration 
procedure and special labelling arrangements are to apply to these products. 
All other homeopathic medicinal products are to be authorized and labelled in 
accordance with the conditions applying to allopathic medicinal products. 
4. Proposed amendments to the Commission proposal 
The Commission proposal has great merits, but several points need to be 
formulated more precisely because as it stands many patients and doctors (and 
healers) are left out of account. 
First, it needs to be made clear in the recitals that patients have the right 
to choose the type of treatment they receive, whether this is allopathic, 
homeopathic or of some other type. Second, the directive should seek to help 
in bridging the gap between allopathic and homeopathic treatment, of which 
much is still currently being made, and to increase the awareness that both 
types can complement each other. 
Furthermore, the directive should incorporate anthroposophical medicine. In 
the Federal Republic of Germany, in particular, this represents one of the 
OJ No. L 147, 9.6.1975, p. 13 
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most important alternative medicines, and not incorporating it will mean that 
an opportunity has been missed that would benefit the countless patients who 
have chosen this type of medicine. 
A fourth shortcoming in the Commission proposal is the failure to incorporate 
homeopathic and anthroposophical compound medicinal products. These are 
widely used and ignoring them would jeopardize some branches of homeopathy. 
On some other points the Commission has shown excessive caution. Parenteral 
administration should be included in the simplified registration procedure of 
Article 7. In the Federal Republic of Germany homeopathic medicinal products 
are often administered via injections. In the many years that this has been 
normal practice, there have never been any problems. This form of 
administration is also normal in homeopathic veterinary treatment, so that 
suppositories and eye drops should be included in the simplified procedure 
under Article 7. 
The provisions of Article 7 are also too restrictive with regard to the degree 
of dilution. The proposal sets dilutions of one part per million (D6) as the 
limit. However, years of experience have shown that almost all dilutions up 
to 1 part per ten thousand (D4) are totally harmless and satisfy the condition 
that the product must be guaranteed to be harmless. In place of a single 
standard or level of dilutions for all preparations, your rapporteur proposes 
greater differentiation in the regulations so that the permitted quantity of 
an active principle is determined in accordance with the method of 
administration and the degree of toxicity. 
A further sensitive point is Article 9(2), which lays down that homeopathic 
medicinal products must be supported by scientific proof such as applies to 
allopathic medicinal products. This places allopathy on a pedestal. One of 
the causes of the allopathy-homeopathy controversy is precisely that 
conventional medical science does not admit the proof adduced by homeopathic 
doctors. Only rarely are scientific articles about the effectiveness of 
homeopathic medicine accepted by the publishers of conventional medical 
journals. The works of Bernard Pointvin 1 and Rigetti 2 provide thorough 
evidence and contain extensive bibliographical references. Peter Fisher3 has 
drawn up a list of some 160 studies on the effects of homeopathy. The proof 
required by Article 9(1) should therefore take into account the basic 
principles and special nature of homeopathy. 
The same applies to anthroposophical medicine. To apply to these types of 
treatment the same standard as to allopathic medicine is at variance with the 
very philosophy behind them. Furthermore, the fact that conventional medicine 
cannot comprehend homeopathic and anthroposophical medicines does not mean 
that they do not work. The long experience of tens of thousands of homeopaths 
and anthroposophy doctors and of millions of patients in and outside the 
Community is ample proof that these treatments have their merits and are 
indeed highly effective. 
2 
3 
Bernard Pointvin: Le devenir de l'homeopathie, Doin, Paris, 1987 
ISBN 2-7040-053-1 
Rigetti: Forschung in der Homepathie, Burgdorf, Gottingen, 
ISBN 3-922345-39-5 
Dr Peter Fisher: Research in Homeopathy - A Bibliography, 5th edition, 1989 
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The regrettable resistance of conventional medicine to homeopathic and 
anthroposophical medicine can be explained in part from the Cartesian-
Newtonian framework which applies within conventional medicine. 
5. Conclusions 
The Commission's proposals concerning the placing on the market of homeopathic 
medicinal products for human use and of homeopathic veterinary products should 
thus be fully endorsed, provided that some points are clarified. 
In the interests of public health and consumer protection it is important for 
the Commission to submit proposals without delay to regulate the practice of 
homeopathic and anthroposophical medicine (and indeed all alternative 
medicines). Since these medicines are enjoying (slightly) rising interest 
amongst consumers, there is a danger that without legislation amateurs will 
take over part of the market. 
In order to give homeopathic and anthroposophical medicine the same 
opportunities as allopathic medicine and to safeguard consumer choice of 
treatment, the companies which reimburse medical expenses must not make a 
distinction between the therapy chosen. Currently the cost of homeopathic 
treatment is reimbursed only in France, Germany, the UK and in some cases the 
Netherlands. 
Finally, it is desirable for the EC to contribute to the creation of a 
European pharmacopoeia and a data bank for homeopathic and anthroposophical 
medicinal products. 
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OPINION 
(Rule 37 of the Rules of Procedure) 
of the Committee on Economic and Monetary Affairs and Industrial Policy 
Craftsman: Mrs Brigitte ERNST de la GRAETE 
At its meeting of 17 July 1990 the Committee on Economic and Monetary Affairs 
and Industrial Policy appointed Mrs ERNST de la GRAETE draftsman. 
At its meetings of 19-21 September and 15 and 16 October 1990 the committee 
considered the draft opinion. 
At the latter meeting it adopted the conclusions as a whole by 17 votes to 20. 
The following took part in the vote: Beumer, chairman; Fuchs, vice-chairman; 
Ernst de la Graete, draftsman; Bofill Abeilhe, Cassidy, Cox, Herman, Hoff, 
Metten, Merz,, Lulling, Pinxten, Rogalla, Sboarina, Martinez (for Megret), 
Peter (for Ford), Porto (for Visentini), Titley (For Read) and Van der Waal 
(for Lataillade). 
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I. ANALYSIS OF THE SUBSTANCE OF THE PROPOSALS 
1. Need for approximation of the laws of the Member States 
To date, there have been no measures to harmonize the law on homeopathic 
medicinal products for human or veterinary use. Discrepancies between 
existing bodies of legislation applied to homeopathic medicinal products, 
however, jeopardize the completion of the internal market in that domain. 
Although homeopathic medicine has been practised for over 200 years, its 
status varies from one Member State to another. While some Member States 
traditionally recognize homeopathy, in others it is merely tolerated or 
completely ignored. 
Yet a demand for alternative medicine exists. A recent study4 shows 
that 18 to 75% of the population, depending on the EEC country concerned, 
use these medicines. The most popular alternative treatments are 
firstly, homeopathy, then acupuncture, chiropractic and herbal remedies. 
Those using such medicine are generally adults (from 40 to 60 years old) 
with a high level of education. 
Although almost unanimously rejected by scientific op1n1on, these 
methods can appeal to patients disappointed by the impersonal and 'high-
tech' nature of modern medicine. They are based on holistic methods of 
treatment, taking account not only of the patient's physical condition 
but also of his psychological and spiritual state. They have the 
further attraction of encouraging the patient to participate more fully 
in the healing process. 
Finally, although homeopathic remedies account for only a small share of 
the market in pharmaceuticals, that nevertheless represents some half a 
billion ECU per year5 
It is appropriate, therefore, from the point of view of both patient 
safety and the completion of the internal market in the pharmaceutical 
sector, to seek harmonization in this field, while ensuring that patients 
have easy access to homeopathic products within the Community area, in 
accordance with the principle of the free movement of goods. 
2. The proposed system 
4 
5 
The proposals in question are intended to harmonize the legislation 
covering homeopathic medicinal products for human or veterinary use. 
These proposals apply to homeopathic medicinal products as defined in the 
European Pharmacopoeia or, failing that, in national pharmacopoeias. 
They cover only medicines which are widely distributed, in other words 
those prepared industrially; preparations prescribed in individual cases 
would not be affected. 
Study by G. Sermus: Alternative Medicine in Europe, Ed. Belgian Consumers' 
Association, Brussels, November 1987 
Moreover, this turnover does not give a true picture of the extent of the 
homeopathic sector. Given the relatively low price of homeopathic 
medicinal products, the number of consumers is in fact greater than one 
would assume from the turnover involved. 
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(a) Manufacture 
In future, homeopathic medicinal products produced in the Community 
must meet the standards for manufacture and monitoring laid down in 
Chapter IV of Directive 75/319/EEC: authorization to manufacture, 
export or import such products will be conditional on possession 
of suitable premises and equipment; each batch manufactured will 
have to be monitored by a qualified person; the rules of good 
manufacturing practice (GMP) will become mandatory. 
(b) Patient safety and information 
Bringing the preparation of homeopathic medicinal products within 
the scope of the manufacturing and monitoring rules laid down in 
Directive 75/319/EEC will offer patients a degree of protection 
against various sharp practices. 
Moreover, Articles 2 and 7 contain provisions to ensure that 
patients are clearly informed of the fact that the product is a 
homeopathic remedy, the scientific name of the stock and the 
degree of dilution. 
(c) Marketing of products 
Two methods of placing products on the market are proposed. 
The first consists of a simplified registration procedure for 
medicinal products marketed without any specific therapeutic 
indication, administered orally or externally and in a sufficient 
degree of dilution to guarantee the safety of the preparation. 
This means that these products will be subject to the rules of 
procedure laid down in Articles 5 to 12 of Directive 65/65/EEC, 
except that proof of therapeutic effect will not be required. 
Other homeopathic medicinal products will be subject to the 
ordinary rules on market authorization, especially criteria of 
efficacy and safety, that apply to allopathic medicinal products. 
However, Member States may decide to apply special rules to 
homeopathic medicine, in which case (Article 9(2)) they must notify 
the Commission of the specific rules in force. Finally, the 
directive, which should be applied by 31 December 1992 at the 
latest, has no retrospective force. 
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II. COMMENTS ON THE PROPOSALS 
1. Good features of the proposals 
We approve the Commission's two proposals to extend to homeopathic 
medicinal products for human or veterinary use the prov1s1ons of 
Directives 65/65/EEC and 75/319/EEC on allopathic medicinal products. We 
also consider it reasonable to introduce a simplified registration 
procedure for a particular category of homeopathic medicinal products 
that are relatively innocuous in view of their high degree of dilution. 
These provisions will offer patients fuller information and increased 
safety while making the products more easily available inside Community 
territory in accordance with the objectives of Article 100a. 
However, the impact of these measures on homeopathic medicine will 
remain limited until the Member States harmonize their respective 
legislation and their approach to alternative medicine in general. It 
is essential, therefore, to promote the creation of a European 
homeopathic pharmacopoeia under the auspices of the Council of Europe. 
Finally, the process of recognizing and organizing homeopathic medical 
practices at European level should also lead to further reflection both 
on the status of homeopathic practitioners, who are legally entitled to 
issue prescriptions, and on whether the cost of homeopathic medicinal 
products should be reimbursed from social security funds. 6 
The refusal by social security authorities to bear or refund the cost of 
such medicines constitutes a distortion of competition which is 
incompatible with the basic principles of the Single Internal Market. 
This discrimination against homeopathic medicine will become unacceptable 
once they are covered by European safety standards. 
2. Suggested amendments 
6 
The text of the Commission's proposal should be amended in various 
respects. 
The wording of Article 7 should be amended to avoid limiting their 
therapeutic applications and the information provided for patients. The 
criteria listed in this Article should be regarded as a minimum. The 
phrase 'by successive dilutions' in the second paragraph of Article 1 
should be defined more precisely, while the first paragraph should be 
expanded. 
Article 6 should be expanded by the addition of Article 3, from Chapter 
Ill, Article 9(1) of Directive 85/570/EEC of 26 October 1983 to enable 
the proposed system to be set up more swiftly. 
Article 9, also, should be amended. For the sake of consistency and to 
avoid discriminating against homeopathic products, proof of therapeutic 
effect, if required, should not be conditional on clinical trials in 
accordance with allopathic practice. The methods of testing used should 
be those applied in homeopathic schools of medicine. 
Only France, the FRG and, to some extent, the Netherlands and the United 
Kingdom allow the cost of homeopathic medicines to be reimbursed by social 
security bodies. 
DOC_EN\RR\107695 - 26 - PE 144.139/fin. 
Finally, the Member Stat<::s should not be allowed to maintain special 
rules for pharmacological and toxicological tests and clinical trials of 
homeopathic medicines. This option would both limit the impact of the 
directive and lead to discrimination and distortion of competition. 
The proposed amendments also apply to the identical text of the proposal 
for a directive on homeopathic medicinal products for veterinary 
purposes. We add, however, an additional amendment to Article 7(1) to 
take account of the frequent use by homeopathic veterinary surgeons of 
parenteral injections. 
PROPOSED AMENDMENTS 
COM(90) 72 final - SYN 251 
Commission text Amendments 
Amendment No. 1 
First recital 
Whereas differences currently 
existing between the provisions laid 
down by law, regulation or 
administrative action in the Member 
States may hinder trade in 
homeopathic medicinal products within 
the Community; 
Whereas differences currently 
existing between the provisions laid 
down by law, regulation or 
administrative action in the Member 
States may hinder trade in 
homeopathic medicinal products 
within the Community and thus lead 
to discrimination and distortion of 
competition between manufacturers; 
Amendment No. 2 
Article 1, first paragraph 
For the purpose of this Directive, 
'pomeopathic medicinal product' shall 
mean any medicinal product prepared 
in accordance with a homeopathic 
manufacturing procedure described by 
the European Pharmacopoeia, or in the 
absence thereof, by the official 
pharmacopoeia of a Member State; 
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For the purpose of this Directive, 
'homeopathic medicinal product' 
shall mean any medicinal product 
containing one or more ingredients 
prepared in accordance with a 
homeopathic manufacturing procedure 
described by the European 
Pharmacopoeia, or in the absence 
thereof, by the official 
pharmacopoeia of a Member State; 
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Amendment No 3 
Article 7(1) 
1. Homeopathic medicinal products 
shall be subject to a simplified 
registration procedure if they 
satisfy all of the following 
conditions: 
they are administered orally or 
externally; 
1. Homeopathic medicinal products 
shall be subject to a 
simplified registration 
procedure if they satisfy all 
of the following conditions: 
they are administered in 
accordance with the methods of 
administration described by 
the European Pharmacopoeia or, 
in the absence thereof, by the 
official pharmacopoeia of a 
Member State; 
- they are marketed without any 
specific therapeutic 
indication, whether on the 
labelling of the product or in 
any accompanying product 
information; 
unchanged 
- there is a sufficient degree of 
dilution to guarantee the 
safety of the preparation; in 
particular, the preparation 
shall contain less than one 
part per million of any active 
principle which is subject to 
the requirement of a medical 
prescription. 
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there is a sufficient degree 
of dilution to guarantee the 
safety of the preparation; 
however, the authority 
responsible for granting 
authorization may require the 
submission of documents 
concerning the toxicological 
properties of a medicinal 
product proving its safety 
when used in normal 
circumstances if the degree of 
dilution is such that the 
preparation contains more than 
one part per million of any 
active principle which is 
subject to the requirement of 
a medical prescription. 
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Amendment No. 4 
Article 7(2) 
2. In addition to the clear mention 
of the words 'homeopathic 
medicinal product', the labelling 
and packaging of the homeopathic 
medicinal products referred to in 
paragraph 1 shall consist of the 
following information and no 
other information: 
- the scientific name of the 
stock followed by the degree of 
dilution, using the symbols used 
in the official pharmacopoeia of 
the Community, 
(rest unchanged) 
2. In addition to the clear 
mention of the words 
'homeopathic medicinal 
product', the labelling and 
packaging of the homeopathic 
medicinal products referred to 
in paragraph 1 shall consist 
of at least the following 
information: 
the scientific name of the 
stock(§.) followed by the 
degree(§.) of dilution, using 
the symbols used in the 
official pharmacopoeia of the 
Community, 
galenic form and presentation; 
(rest unchanged) 
PROPOSALS FOR AMENDMENTS 
COM(90) 72 final - SYN 252 
Amendments Nos. 1, 2 and 4 are identical 
Amendment No. 3 
Article 7(1) 
1. Homeopathic veterinary medicinal 
products shall be subject to a 
simplified registration procedure 
if they satisfy all of the 
following conditions: 
they are administered orally or 
externally; 
(rest unchanged) 
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1. Homeopathic veterinary 
medicinal products shall be 
subject to a simplified 
registration procedure if they 
satisfy all of the following 
conditions: 
they are administered orally, 
externally or parenterally; 
(rest unchanged) 
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CONCLUSIONS 
1. Homeopathy, a form of alternative medicine that is generally fairly 
inexpensive and sometimes complementary to allopathic (i.e. orthodox) 
medicine, meets a distinct need since between 18 and 75% of the population 
make use of this form of medicine, which has an annual turnover of about 
half a billion ECU. 
2. It is, therefore, necessary to ensure, in accordance with Article 100a of 
the Treaty, the free movement of such products while providing that the 
best possible safety guarantees exist for patients. 
3. This is the objective of the Commission 1 s proposals, which seek to make 
homeopathic medicinal products for human or veterinary use subject to the 
rules laid down in Directives 65/65/EEC and 75/319/EEC on monitoring and 
controlling the manufacture of medicines and the conditions in which they 
are freely available in the Community. 
4. Further, the Commission 1 s proposals lay down a simplified registration 
procedure which is justified in the case of those homeopathic medicinal 
products which are relatively innocuous in view of their high level of 
dilution and the method by which they are administered. 
5. However, these proposals should be amended to enhance patient safety and 
information (Articles 1 and 7). 
6. The two proposals for directives should, therefore, be approved, 
to the above proposals for amendments, which the Committee 
Environment, Public Health and Consumer Protection is requested 
into account. 
subject 
on the 
to take 
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OPINION 
OF THE COMMITTEE ON AGRICULTURE, FISHERIES AND RURAL DEVELOPMENT 
Letter from Mr COLINO SALAMANCA, chairman of the Committee on Agriculture, 
Fisheries and Rural Development, to Mr K.D. COLLINS, chairman of the Committee 
on the Environment, Public Health and Consumer Protection 
Brussels, 17 October 1990 
Subject: Proposal for a Council Directive widening the scope of Directives 
65/65/EEC and 75/319/EEC on the approximation of the laws of the 
Member States on medicinal products and laying down additional 
provisions on homeopathic medicinal products 
and 
Proposal for a Council Directive widening the scope of Directive 
81/851/EEC on the approximation of the laws of the Member States on 
veterinary medicinal products and laying down additional provisions 
on homeopathic veterinary medicinal products 
(COM(90) 72 final -Doe. C3-112/90 and Doe. C3-113/90) 
Dear Mr Chairmpn, 
At its meeting of 15/16 October 19907 , the Committee on Agriculture, Fisheries 
and Rural Development considered the above proposals, on which your committee 
is currently drawing up a report. 
These two proposals for directives are aimed at harmonizing the market in 
homeopathic medicines for both human and animal use, which were provisionally 
excluded from Community pharmaceutical legislation in 1975. 
In fact, two different conceptions of medicine are involved: 
7 
allopathic medicine, the dominant tradition in Western Europe, is based on 
the concept of 'curing by opposites' - a maxim attributed to Galen, which 
underlies the use of 'anti' -drugs such as antibiotics, anti-inflammatory 
agents and painkillers; 
homeopathic medicine 'makes use of substances which produce systems similar 
to those of the illness concerned in healthy individuals'. The term 
'homeopathy', coined by the German Hahnemann (1755-1843) and first used in 
1810, derives from the Greek words homoios (equal) and pathos (suffering). 
The following took part in the vote: COLINO SALAMANCA, chairman; GRAEFE ZU 
BARINGDORF, vice-chairman; BLANEY, CARVALHO CARDOSO, DOMINGO SEGARRA, 
GARCIA, GORLACH, LIVANOS, MARCK, ORTIZ CLIMENT, PARTSCH (for FALQUI), 
Feruccio PISONI (for Nino PISONI), SONNEVELD, VERBEEK, VOHRER 
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Homeopathic medicines are prepared from substances which cause similar 
reactions to the symptoms of the illness concerned but are diluted at a ratio 
of 1 to 1012 so that the solution no longer contains a single molecule of the 
original substance, while retaining its dynamic agency. The active capacity 
of such diluted preparations is questioned by conventional medicine, 
especially as they do not permit the use of the statistical methods of 
clinical tests. 
Homeopathic medicine 
homeopathic medicines 
pharmaceuticals. 
is officially 
account for 
recognized in some 
approximately 2% of 
Member States; 
the market in 
The implementation of these directives will provide the Community consumer 
with a guarantee of the quality and safety of homeopathic medicines, in line 
with the existing requirements for other medicines. In the veterinary field, 
there is a further requirement that homeopathic treatment of animals should 
not leave harmful residues in food products. 
The accepted manufacturing procedures are those set out in the official 
pharmacopoeias of individual Member States, given the lack of a European 
Pharmacopoeia. 
Parliament has given its favourable op1n1on on the package of measures for the 
completion of the internal market, aimed at the elimination of obstacles to 
intra-Community trade while safeguarding human and animal health. 
The Committee on Agriculture, Fisheries and Rural Development considers that 
these two proposals for directives represent a further necessary step in the 
completion of the process, and therefore favours their adoption. 
Yours faithfully 
Juan Luis COLINO SALAMANCA 
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